Cover Image
市場調查報告書

鼻竇炎:開發中產品分析

Sinusitis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232858
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
鼻竇炎:開發中產品分析 Sinusitis - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 82 Pages
簡介

所謂鼻竇炎是指鼻子的發炎,一般是病毒或是細菌感染引起的,也有可能是過敏引起。症狀有鼻塞、疼痛、壓痛、嗅覺障礙、口臭、咳嗽、牙痛、頭痛、頰骨痛等。危險因子有氣喘、鼻腔異常、HIV/AIDS和囊狀纖維化症等免疫系障礙、過敏等。

本報告提供鼻竇炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

鼻竇炎 概要

治療藥的開發

  • 開發中產品;概要
  • 企業開發中的治療藥
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AmpliPhi Biosciences Corp
  • F. Hoffmann-La Roche Ltd
  • Knopp Biosciences LLC
  • 杏林藥業
  • Kyowa Hakko Kirin
  • Merck & Co Inc
  • OptiNose US Inc
  • Pfizer Inc
  • Quorum Innovations LLC
  • Regeneron Pharmaceuticals Inc
  • Therabron Therapeutics Inc

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9715IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis - Pipeline Review, H2 2017, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.

Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sinusitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 3, 4 and 1 respectively.

Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sinusitis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sinusitis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sinusitis - Overview
    • Sinusitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Sinusitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Sinusitis - Companies Involved in Therapeutics Development
    • AmpliPhi Biosciences Corp
    • F. Hoffmann-La Roche Ltd
    • Knopp Biosciences LLC
    • Kyorin Pharmaceutical Co Ltd
    • Kyowa Hakko Kirin Co Ltd
    • Merck & Co Inc
    • OptiNose US Inc
    • Pfizer Inc
    • Quorum Innovations LLC
    • Therabron Therapeutics Inc
  • Sinusitis - Drug Profiles
    • ABSA-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benralizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexpramipexole dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluticasone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lascufloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PCL-1550 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06817024 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qi-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-6149 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chronic Rhinosinusitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sinusitis - Dormant Projects
  • Sinusitis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 17, 2017: AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal
      • Apr 04, 2017: AmpliPhi Biosciences Presents Clinical and Preclinical Data of Pipeline Program AB-SA01 at Two Scientific Conferences
      • Mar 07, 2017: Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials
      • Dec 19, 2016: AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients
      • Oct 25, 2016: AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis
      • Sep 20, 2016: AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients
      • Sep 16, 2016: OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis with and without Nasal Polyps
      • Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress
      • Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus
      • Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
      • Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01
      • Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections
      • Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Sinusitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Sinusitis - Pipeline by AmpliPhi Biosciences Corp, H2 2017
  • Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Sinusitis - Pipeline by Knopp Biosciences LLC, H2 2017
  • Sinusitis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Sinusitis - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Sinusitis - Pipeline by Merck & Co Inc, H2 2017
  • Sinusitis - Pipeline by OptiNose US Inc, H2 2017
  • Sinusitis - Pipeline by Pfizer Inc, H2 2017
  • Sinusitis - Pipeline by Quorum Innovations LLC, H2 2017
  • Sinusitis - Pipeline by Therabron Therapeutics Inc, H2 2017
  • Sinusitis - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Sinusitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top